MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec for the Treatment of X-linked Retinitis Pigmentosa
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
Golconda Gold Releases Q2 2026 Production Update at Galaxy And Announces Mobilisation of Mining Contractor at Summit
New Report from KBR Supports Potential for US$1.75/kg Hydrogen from Syntholene's Geothermal-SOEC Platform
